Novartis (NYSE: NVS) Q3 Earnings: Revenue Miss, EPS Beat, and Raised Outlook

By Rayan Ahmad27 Oct, 15:06From Financial Modeling Prep

Key points

Novartis (NYSE: NVS) reported strong earnings per share of $2.46, surpassing analyst estimates of $2.25, despite a slight miss on revenue at $14.52 billion against an expected $14.53 billion.
The global drugmaker demonstrated robust sales growth, with revenue increasing from $13.91 billion a year earlier, driven in part by key products like its top-selling breast cancer treatment, Kisqali.
The company raised its 2026 outlook for core operating income to low-single-digit growth, a significant improvement from a previous forecast of a low-single-digit decline, leading to a 1% rise in Novartis shares during premarket trading.

Novartis (NYSE: NVS) reports third-quarter earnings before the market opens on October 27, 2026. The global drugmaker sells treatments for cancer and other diseases, competing with large pharmaceutical companies for patients and new drug approvals. Earnings per share are $2.46, above the $2.25 estimate, while revenue of $14.52 billion is just below the $14.53 billion estimate.

Revenue rises from $13.91 billion a year earlier, showing strong sales growth despite the small miss against expectations. Earnings per share also rise from $2.25 a year earlier to $2.46. This measure shows how much profit the company earns for each share.

Kisqali, Novartis’s top-selling breast cancer treatment, brings in $1.82 billion, below the $1.84 billion expected. Novartis raises its 2026 outlook for core operating income to low-single-digit growth from a low-single-digit decline. It keeps its forecast for mid-single-digit sales growth. Core operating income measures profit from regular business activities.

Shares of Novartis rise about 1% to $154.91 in premarket trading, as highlighted by Investors.com. The positive investor response comes despite the revenue miss and clinical-trial setbacks that weigh on third-quarter profit, as highlighted by The Wall Street Journal. Novartis says sales growth and productivity gains support its higher profit outlook.